Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research

ConditionsPost-Acute COVID-19 Syndrome ME/CFS Rheumatic Arthritis Juvenile Rheumatoid Arthritis (JRA)Psoriatic Arthritis (PsA)Ankylosing Spondylitis (AS)Autoimmune Encephalitis Celiac Disease Celiac Disease in Children Chronic Lyme Disease Post-treatment Lyme Disease Syndrome Crohn's Disease Dysautonomia Anorexia Nervosa Bulimia Nervosa ARFID Avoidant / Restrictive Food Intake Disorder Ehlers Danlos Syndrome Endometriosis Fibromyalgia (FM)Long COVID Lupus Migraines Mast Cell Activation Syndrome Multiple Sclerosis Myalgic Encephalomyelitis (ME)Myasthenia Gravis, Generalized Myasthenia Gravis in Children Narcolepsy Obsessive Compulsive Disorder (OCD)PANDAS Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)POTS - Postural Orthostatic Tachycardia Syndrome General Anxiety Disorder, Social Anxiety Disorder PTSD - Post Traumatic Stress Disorder Psoriasis Traumatic Brain Injury Tourette's Syndrome Inflammatory Bowel Disease (IBD)Autoimmune Diseases Neurological Diseases or Conditions Psychiatric Disorder Sjogren's Syndrome Ulcerative Colitis and Crohn's Disease

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age2+

SponsorBrain Inflammation Collaborative

About this trial

The unhide® Project is a non-interventional, longitudinal research study designed to establish a secure data repository of demographic, health, and lifestyle information from individuals with brain inflammation and related neuroinflammatory conditions. Participants in the United States aged 2 years and older will provide self-reported health data, biometrics, and symptom diaries through the MyDataHelps™ app (branded as unhide® for this study). The goal is to create comprehensive longitudinal profiles to facilitate research into disease subtypes, causes, diagnostics, and potential treatments, as well as to identify potential participants for future optional studies. "Healthy" individuals without brain inflammation are also eligible to participate.

The digital health research platform used in this study was originally developed and designed by Solve M.E and was called SolveTogether. The Brain Inflammation Collaborative (BIC) expanded upon Solve M.E.'s work to include related diagnoses, pediatric participants, enhance symptom tracking, and more. BIC and Solve M.E. combined Solve Together and unhide®, to create The unhide® Solve Together Unified Platform in 2025.

Eligibility criteria

Qualifiers

Infection-associated chronic conditions such as Long COVID, chronic Lyme, myalgic encephalomyelitis (ME/CFS), and post-acute neuropsychiatric syndrome (PANS/PANDAS).

Neuroimmune, developmental, autonomic, and neurological conditions like migraines, dysautonomia, POTS, multiple sclerosis, and autism spectrum disorder.

Autoimmune diseases such as Lupus, Sjogren's Disease, rheumatoid arthritis, myasthenia gravis, ankylosing spondylitis, and related autoimmune conditions.

Behavioral and mood disorders such as anxiety, depression, bipolar disorder, PTSD, eating disorders, OCD, and other related conditions.

Disqualifiers

None

Trial design

Treatments tested in this trial

Not listed

Trial groups

10,000 Participants

are grouped into 2 trial groups

Sponsors and collaborators

Brain Inflammation Collaborative

Lead sponsor

Solve ME/CFS Initiative

Collaborator

Care Evolution

Collaborator

Columbia University

Collaborator

Source ClinicalTrials.gov